The News Review:

- Aprotinin associated with increased risk of death
- Some Programs Aim to Boost
- Critical Biologics Commences Clinical Testing of Solinex(TM)
- Talecris Announces 2008 Application Cycle for Talents Research…

Aprotinin associated with increased risk of death
EurekAlert – EurekAlert (press release) – May 14, 2008
BART has shown us that tranexamic acid or aminocaproic acid are safer choices for cardiac surgical patients even in high risk patients. Peter Liu MD MSc Scientific Director of CIHR’s Institute of Circulatory and Respiratory Health and Champion of the Clinical Research Initiative: “This finding will improve the heart health of Canadians while reducing the risk of drug complications. It is only through this type of clinical research involving federal provincial university and hospital partners that we can significantly improve health of Canadians and our health system. Stewart MD CE and Scientific Director of the ttawa Health Research Institute Vice President of Research at The ttawa Hospital and Professor of Medicine at the University of ttawa: “The ttawa Health Research Institute is pleased to have supported its Scientists in performing this crucial research that I believe will contribute to better safer management of bleeding during major heart surgery. Jacques Bradwejn MD Dean of the Faculty of Medicine at the University of ttawa: “The BART study illustrates the importance of clinical studies designed by independent university researchers to answer important questions that can make a real difference in the treatment of patients.

Some Programs Aim to Boost
wsj.com – May 14, 2008
“I always feel like there may be something tomorrow and it gives me a little hope other than going in for chemo every week. The Center for Information and Study on Clinical Research Participation (. org) is trying to raise awareness about the benefits of clinical trials. The group is launching a new public-service ad campaign to portray ordinary Americans who participate in clinical trials as “Medical Heroes” who help save lives and advance medical science. Kenneth Getz the group’s president recently released a book “The Gift of Participation” which offers information to assist patients in deciding whether to participate in clinical trials.

Critical Biologics Commences Clinical Testing of Solinex(TM)
Earthtimes – May 14, 2008
“We are very pleased to be working with such a capable medical institution” he said. “We are especially grateful for the expertise and devotion of the lead investigator and the institution’s team of dedicated clinical trial specialists. In CBC’s previous 200 patient plasma gelsolin epidemiology study this group proved themselves to be a highly competent team of clinical research professionals. Their world-class medical care compliance to trial procedures strict adherence to EU and FDA guidelines and ability to rapidly accrue patients make them an ideal clinical research partner for a development stage company like CBC. ” About Plasma Gelsolin Gelsolin is a highly evolutionary conserved naturally occurring protein found inside cells as well as in plasma. Circulating plasma gelsolin (pGSN) levels decrease shortly after a variety of tissue injuries such as trauma major surgery burns and sepsis. Severe depletion of pGSN has been found to correlate strongly with adverse clinical outcomes in critical care patients such as longer ventilator times longer duration of ICU stays and death.

Talecris Announces 2008 Application Cycle for Talents Research…
WebWire – WebWire (press release) – May 14, 2008
(May 2008) The Talecris New Trials Support program (Talents) sponsored by Talecris Biotherapeutics Inc. is now accepting applications for the 2008 research grants cycle. The Talents program entering its third year aims to advance basic and clinical research addressing the use of intravenous immunoglobulin (IGIV) in immunological hematological and neurological indications. Totaling $1 million annually the grants support either a one- or two-year research period and include funding for salary overheads and direct costs. Application ProcessEffective immediately interested investigators are invited to submit a Letter of Intent (LI) to the Talents Evaluation Committee a committee comprised of Talecris scientists and external experts in immunology neurology and hematology. The deadline for submission of an LI for the 2008 cycle is August 4 2008. Upon LI approval by the Evaluation Committee investigators will receive a full application form to be completed by mid-ctober 2008.